David MacManus, Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology.
The NMR Research Unit is internationally recognized for its significant contribution over the last 30 years in advancing the understanding of the disease mechanisms of multiple sclerosis (MS) and in pioneering of new MR techniques.
As a result of the expertise in the area of MRI and MS, collaboration with the pharmaceutical industry has been developed as potential therapies for MS began to be explored. This resulted in the Unit undertaking its first major multicentre MS treatment trial in 1995. Several other contracts followed which resulted in the development of a dedicated trials team being formed – the NMR Research Unit Trials Office, headed by David MacManus.
The team works with sponsors from the pharmaceutical industry, research councils, NHS and medical charities to manage and analyse MRI data acquired as part of multicentre MS treatment trials.